Compare BGSI & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | ADMA |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | N/A | N/A |
| Metric | BGSI | ADMA |
|---|---|---|
| Price | $159.60 | $19.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 20.1K | ★ 2.3M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | 0.74 | ★ 0.86 |
| Revenue | ★ $3,101,279,000.00 | $488,559,000.00 |
| Revenue This Year | $4.03 | $22.19 |
| Revenue Next Year | $26.52 | $23.71 |
| P/E Ratio | $280.27 | ★ $22.52 |
| Revenue Growth | 1.42 | ★ 27.63 |
| 52 Week Low | $136.81 | $13.50 |
| 52 Week High | $177.20 | $25.67 |
| Indicator | BGSI | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.86 |
| Support Level | N/A | $18.33 |
| Resistance Level | N/A | $19.94 |
| Average True Range (ATR) | 0.00 | 0.63 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 0.00 | 45.11 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority, and Autoglassonly.com. In addition, the Company operates a third-party administrator, Gerber National Claims Services (GNCS), that offers glass, emergency roadside, and first notice of loss services.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.